Baxalta Now Part Of Shire
Clinical trials sponsored by Baxalta Now Part Of Shire, explained in plain language.
Baxalta was a biopharmaceutical company acquired by Shire, which is now part of Takeda.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope for kids with rare bleeding disease: study tests rVWF therapy
Disease control CompletedThis study tested a medicine called vonicog alfa (rVWF), sometimes given with another drug (ADVATE), to control bleeding in 47 children under 18 with severe von Willebrand disease. The treatment was given for 12-18 months, and doctors checked how well it stopped bleeding and if i…
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New enzyme therapy shows promise in controlling rare blood clotting disorder
Disease control CompletedThis study tested a medicine called BAX 930 in 52 people born with severe TTP, a rare condition that causes dangerous blood clots. The medicine replaces a missing enzyme to prevent or treat sudden flare-ups. Participants received either BAX 930 or standard treatment for 6 months,…
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
One-Time gene therapy shot aims to ease severe hemophilia a
Disease control CompletedThis early-phase trial tested a gene therapy called BAX 888 in 4 men with severe hemophilia A. The therapy uses a harmless virus to deliver a working gene for factor VIII, a blood-clotting protein they lack. Participants received a single intravenous infusion, and the study focus…
Phase: PHASE1, PHASE2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 26, 2026 16:52 UTC
-
New hope for rare bleeding disorder: Long-Term drug shows promise
Disease control CompletedThis study tested a drug called rVWF (Vonvendi) in 38 children and adults with severe von Willebrand disease, a bleeding disorder. The goal was to see if regular use of the drug could reduce the number of spontaneous bleeding episodes over a year. Participants received treatment …
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 26, 2026 12:56 UTC